文献速递先天性心脏病外科心外重症与机械循环支持

183例儿童或先天性心脏病心脏移植分析:高群体反应性抗体的影响

An Analysis of 183 Heart Transplants for Pediatric or Congenital Heart Disease-Impact of High Panel Reactive Antibody.
PubMed 文献 · Ann Thorac Surg · 2022-11-10

回顾性分析2011年1月1日至2021年12月31日179例儿童和/或先天性心脏病患者接受的183例心脏移植,评估高群体反应性抗体(PRA>10%)的影响。高PRA占32.8%,与既往心脏手术、再次移植和交叉配型阳性相关;多因素分析中高PRA不影响生存,5年生存率相似(log-rank P=0.4),但1年死亡率较高(14.9% vs 3.8%,P=0.035)。作者认为个体化免疫调节策略可能减轻高PRA风险。

要点

  • 183例移植中32.8%为高PRA(>10%),高PRA组交叉配型阳性率40.0% vs 8.9%(P<.0001)。
  • 多因素分析中高PRA不影响生存;5年总体生存高PRA与无高PRA无显著差异(log-rank P=.4)。
  • 高PRA组1年死亡率14.9% vs 3.8%(P=.035),但5年生存相似。

核心结论

  • 本队列中高PRA(>10%)患者5年生存与无高PRA(<10%)患者相似,尽管高PRA患者存在更多危险因素。
  • 作者认为个体化免疫调节策略可能减轻高PRA风险。

研究设计与样本

  • 回顾性分析2011年1月1日至2021年12月31日179例儿童和/或先天性心脏病患者的183例心脏移植。
  • 高PRA定义为PRA>10%,采用Cox比例风险模型评估长期生存的单因素关联,多因素模型估计高PRA对生存的影响。

主要发现

  • 183例移植中60例(32.8%)PRA>10%,高PRA组更可能有既往心脏手术、更多既往心脏手术次数、既往胸骨切开、既往心脏移植和交叉配型阳性(24/60 [40.0%] vs 11/123 [8.9%],P<.0001)。
  • 与长期生存相关的单因素因素包括:获得性心脏病 vs 先天性或再移植(HR 0.18;95%CI 0.053-0.593;P=.005)、既往心脏手术(HR 5.6;95%CI 1.32-23.75;P=.020)、既往心脏手术次数(每增加一次手术HR 1.3;95%CI 1.12-1.50;P=.0004)、单心室(HR 2.4;95%CI 1.05-5.48;P=.038)、术前肾功能不全(HR 3.4;95%CI 1.43-7.49;P=.002)。
  • 多因素分析中,控制单因素分析显示与长期生存相关的各因素后,高PRA不影响生存。
  • Kaplan-Meier生存估计:1年和5年生存率(95%CI)分别为:所有患者93.6%(89.9%-97.3%)和85.8%(80.0%-92.1%);PRA<10%患者96.6%(93.4%-99.9%)和86.7%(79.6%-94.3%);PRA>10%患者86.7%(78.0%-96.4%)和83.8%(74.0%-95.0%)。
  • 高PRA与1年死亡率较高相关(14.9% vs 3.8%,P=.035),但移植后5年Kaplan-Meier总体生存在高PRA与无高PRA患者间无显著差异(log-rank P=.4)。

关键数值与推荐

  • 高PRA定义为PRA>10%。
  • 交叉配型阳性:高PRA组24/60(40.0%)vs 无高PRA组11/123(8.9%),P<.0001。
  • 1年死亡率:高PRA组14.9% vs 无高PRA组3.8%,P=.035。
  • 5年总体生存:高PRA组83.8%(95%CI 74.0%-95.0%)vs 无高PRA组86.7%(95%CI 79.6%-94.3%),log-rank P=.4。

临床怎么用

  • 作者认为个体化免疫调节策略可能减轻高PRA风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We reviewed our management strategy and outcome data for all 179 patients with pediatric and/or congenital heart disease who underwent 183 heart transplants from January 1, 2011, to December 31, 2021, and evaluated the impact of elevated panel reactive antibody (PRA). METHODS: High PRA was defined as PRA >10%. Univariate associations with long-term survival were assessed with Cox proportional hazards models. Impact of high PRA on survival was estimated with multivariable models. RESULTS: PRA >10% was present in 60 of 183 transplants (32.8%), who were more likely to have prior cardiac surgery, higher number of prior cardiac operations, prior sternotomy, prior heart transplant, and positive crossmatch (24 of 60 [40.0%] vs 11 of 123 [8.9%], P < .0001). Univariate associations with long-term survival include acquired heart disease vs congenital or retransplant (hazard ratio [HR], 0.18; 95% CI, 0.053-0.593; P = .005), prior cardiac surgery (HR, 5.6; 95% CI, 1.32-23.75; P = .020), number of prior cardiac operations (HR, 1.3 for each additional surgery; 95% CI, 1.12-1.50; P = .0004), single ventricle (HR, 2.4; 95% CI, 1.05-5.48; P = .038), and preoperative renal dysfunction (HR, 3.4; 95% CI, 1.43-7.49; P = .002). In multivariate analysis, high PRA does not impact survival when controlling for each of the factors shown in univariable analysis to be associated with long-term survival. The Kaplan-Meier method provided the following survival estimates at 1 year (95% CI) and 5 years (95% CI) after cardiac transplantation: All patients, 93.6% (89.9%-97.3%) and 85.8% (80.0%-92.1%); PRA <10%, 96.6% (93.4%-99.9%) and 86.7% (79.6%-94.3%); and PRA >10%, 86.7% (78.0%-96.4%) and 83.8% (74.0%-95.0%). Despite high PRA being associated with higher mortality at 1 year (14.9% vs 3.8%, P = .035), no significant difference exists in Kaplan-Meier overall survival at 5 years posttransplant in patients with and without high PRA (log-rank P = .4). CONCLUSIONS: In our cohort, 5-year survival in patients with high PRA (PRA >10%) is similar to that in patients without high PRA (PRA <10%), despite the presence of more risk factors in those with high PRA. Individualized immunomodulatory strategies can potentially mitigate the risk of high PRA.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Bleiweis MS, Fricker FJ, Peek GJ, et al. An Analysis of 183 Heart Transplants for Pediatric or Congenital Heart Disease-Impact of High Panel Reactive Antibody. Ann Thorac Surg. 2022. PMID: 36370883. doi:10.1016/j.athoracsur.2022.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。